167758-58-9

Basic information

• Product Name: [4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL
• Synonyms: [4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL;[4-(2-Methylimidazol-1-yl)phenyl]methanol95%;Zinc02563833;(4-(2-Methyl-1H-imidazol-1-yl)
• CAS NO: 167758-58-9
• Molecular Formula: C₁₁H₁₂N₂O
• Molecular Weight: 188.23
• Mol File: 167758-58-9.mol

Chemical Properties

• Boiling Point: 388.141 °C at 760 mmHg
• Flash Point: 188.541 °C
• Appearance: /
• Density: 1.144 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: 2-8°C
• PKA: 14.18±0.10(Predicted)
• CAS DataBase Reference: [4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL(167758-58-9)
• EPA Substance Registry System: [4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL(167758-58-9)

Safety Data

• Hazardous Substances Data: 167758-58-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
[4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL is used as a chemical intermediate for the synthesis of potential drug candidates, given its potential pharmacological activities and biological properties.
Used in Medicinal Chemistry:
[4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL is used as a key component in the design and development of new therapeutic agents, leveraging its ability to modulate cellular signaling pathways and exhibit anti-inflammatory effects.
Used in Anti-Inflammatory Applications:
[4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL is used as an anti-inflammatory agent, potentially benefiting the treatment of various inflammatory conditions due to its capacity to influence relevant biological processes.
Used in Cellular Signaling Research:
[4-(2-METHYLIMIDAZOL-1-YL)PHENYL]METHANOL is used as a research tool to study the impact of chemical compounds on cellular signaling pathways, which may contribute to the understanding of disease mechanisms and the development of targeted therapies.

InChI:InChI=1/C11H12N2O/c1-9-12-6-7-13(9)11-4-2-10(8-14)3-5-11/h2-7,14H,8H2,1H3

Upstream product

• 108035-44-5 4-(2-methyl-1H-imidazol-1-yl)benzoic acid ethyl ester 
• 88427-96-7 4-(2-methyl-1H-imidazol-1-yl)benzaldehyde 

Downstream Products

• 763902-92-7 1-(4-Chloromethylphenyl)-2-methyl-1H-imidazole 
• 179420-11-2 ethyl 4-[5-fluoro-3-[4-(2-methylimidazol-1-yl)benzyloxy]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-14-5 4-(3-fluoro-5-{[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy}phenyl)tetrahydro-2H-pyran-4-carboxamide 
• 179420-13-4 4-[5-fluoro-3-[4-(2-methylimidazol-1-yl)benzyloxy]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxylic acid 

Relevant articles and documents

Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase

Replacement of the dihydroquinolinone pharmacophore of Zeneca's ZD2138 by ionizable imidazolylphenyl moiety has lead to the discovery of a novel series of potent and orally active 5-lipoxygenase (5-LO) inhibitors. The synthesis and structure-activity relationship (SAR) of this series of compounds are described herein.

5-lipoxygenase inhibitors

Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having the following formula I: STR1 and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, py

Imidazole lipoxygenase inhibitors

Certain novel imidazole derivatives having the ability to inhibit the lipoxygenase enzyme and having formula (I), wherein Y is hydrogen, C1 -C8 alkyl, halosubstituted C1 -C4 alkyl, phenyl, substituted phenyl, C7 -C14 phenylalkyl, C7 -C14 (substituted phenyl)alkyl, pyridyl, substituted pyridyl, C6 -C13 pyridylalkyl or C6 -C13 (substituted pyridyl)alkyl, wherein each substituent is independently halo, nitro, cyano, C1 -C4 alkyl, C1 -C4 alkoxy, halosubstituted C1 -C4 alkyl, halosubstituted C1 -C4 alkoxy, NR4 R5, CO2 R4 or CONR4 R5, wherein R4 and R5 are each, independently, hydrogen or C1 -C6 alkyl; Ar1 and Ar2 are each, independently, phenylene, mono-substituted phenylene or di-substituted phenylene, wherein the substituents are, independently, halo, C1 -C4 alkyl, C1 -C4 alkoxy, halo-substituted C1 -C4 alkyl or halo-substituted C1 -C4 alkoxy; X and X1 are each, independently, O, S, SO or SO2 ; R' is hydrogen or C1 -C4 alkyl; and R2 and R3 are each, independently, methylene, ethylene or propylene. These compounds are useful for the treatment of disease states such as bronchial asthma, skin disorders and arthritis in mammals, and as the active ingredient in pharmaceutical compositions for treating such conditions.